Related Experiment Video
Updated: Apr 23, 2026
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Management of hyperkalaemia in chronic kidney disease
1University of Tennessee Health Science Center, University of Tennessee, 956 Court Avenue, Memphis, TN 38163, USA.
Insights
Hyperkalaemia is a common complication in chronic kidney disease (CKD) patients, often caused by kidney dysfunction and comorbidities. New medications may shift focus to preventing high potassium levels rather than just treating them.
Area of Science:
- Nephrology
- Internal Medicine
- Cardiology
Background:
- Hyperkalaemia is prevalent in chronic kidney disease (CKD) due to impaired potassium homeostasis and comorbidities.
- Severe hyperkalaemia is a medical emergency requiring immediate intervention.
- Long-term management of hyperkalaemia in CKD is challenging, often involving difficult trade-offs with essential medications like renin-angiotensin-aldosterone-system antagonists.
Purpose of the Study:
- To discuss the challenges in managing hyperkalaemia in CKD patients.
- To highlight the limitations of current interventions for chronic potassium balance.
- To explore the potential impact of novel hyperkalaemia-targeting medications on therapeutic strategies.
Main Methods:
- Review of existing literature on hyperkalaemia in CKD.
- Analysis of the interplay between CKD treatments and potassium homeostasis.
- Discussion of current and emerging therapeutic options for hyperkalaemia management.
Main Results:
- Current management strategies for chronic hyperkalaemia in CKD are limited.
- Discontinuation rates of beneficial medications due to hyperkalaemia are high.
- New medications targeting hyperkalaemia offer potential for a paradigm shift towards preventive care.
Conclusions:
- Effective and safe long-term management of hyperkalaemia in CKD remains a significant clinical challenge.
- Balancing the benefits of essential CKD medications with the risk of hyperkalaemia is difficult.
- Emerging therapies may enable a proactive approach to hyperkalaemia, shifting focus from emergency treatment to prevention.
Abstract:
Hyperkalaemia is common in patients with chronic kidney disease (CKD), in part because of the effects of kidney dysfunction on potassium homeostasis and in part because of the cluster of comorbidities (and their associated treatments) that occur in patients with CKD. Owing to its electrophysiological effects, severe hyperkalaemia represents a medical emergency that usually requires prompt intervention, whereas the prevention of hazardous hyperkalaemic episodes in at-risk patients requires measures aimed at the long-term normalization of potassium homeostasis. The options for effective and safe medical interventions to restore chronic potassium balance are few, and long-term management of hyperkalaemia is primarily limited to the correction of modifiable exacerbating factors. This situation can result in a difficult trade-off in patients with CKD, because drugs that are beneficial to these patients (for example, renin-angiotensin-aldosterone-system antagonists) are often the most prominent cause of their hyperkalaemia. Maintaining the use of these beneficial medications while implementing various strategies to control potassium balance is desirable; however, discontinuation rates remain high. The emergence of new medications that specifically target hyperkalaemia could lead to a therapeutic paradigm shift, emphasizing preventive management over ad hoc treatment of incidentally discovered elevations in serum potassium levels.
More Related Videos
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:20Acute Kidney Injury V: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:22Acute Kidney Injury VI: Nursing Management
01:25Chronic Kidney Disease I: Introduction
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention